Basilea Shares Rise on $89M BARDA Contract for BAL30072
Shares in Basilea Pharmaceutica AG gained as much as 6 percent during mid-morning trading Tuesday on news that it secured a contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA), worth up to $89 million, for the development of its antibiotic, BAL30072.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST